86 related articles for article (PubMed ID: 20594155)
1. Synthesis and activity of N-sulfonylamides of tripeptides as potential urokinase inhibitors.
Markowska A; Bruzgo I; Miltyk W; Midura-Nowaczek K
Protein Pept Lett; 2010 Oct; 17(10):1300-4. PubMed ID: 20594155
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Biological Activity of
Markowska A; Bruzgo M; Gorodkiewicz E; Surażyński A
Int J Pept Res Ther; 2013; 19(3):191-198. PubMed ID: 23926446
[TBL] [Abstract][Full Text] [Related]
3. Tripeptides with non-code amino acids as potential serine proteases inhibitors.
Markowska A; Bruzgo M; Surażyński A; Midura-Nowaczek K
J Enzyme Inhib Med Chem; 2013 Jun; 28(3):639-43. PubMed ID: 22299583
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and activity of amides of tripeptides as potential urokinase inhibitors.
Markowska A; Bruzgo I; Midura-Nowaczek K
J Enzyme Inhib Med Chem; 2010 Feb; 25(1):139-42. PubMed ID: 20030517
[TBL] [Abstract][Full Text] [Related]
5. Peptides with 6-Aminohexanoic Acid: Synthesis and Evaluation as Plasmin Inhibitors.
Purwin M; Markowska A; Bruzgo I; Rusak T; Surażyński A; Jaworowska U; Midura-Nowaczek K
Int J Pept Res Ther; 2017; 23(2):235-245. PubMed ID: 28491013
[TBL] [Abstract][Full Text] [Related]
6. The Effects of a Novel Series of KTTKS Analogues on Cytotoxicity and Proteolytic Activity.
Tałałaj U; Uścinowicz P; Bruzgo I; Surażyński A; Zaręba I; Markowska A
Molecules; 2019 Oct; 24(20):. PubMed ID: 31618846
[TBL] [Abstract][Full Text] [Related]
7. Simplified, serine-rich theta-defensin analogues as antitumour peptides.
Strzelecka P; Czaplinska D; Sadej R; Wardowska A; Pikula M; Lesner A
Chem Biol Drug Des; 2017 Jul; 90(1):52-63. PubMed ID: 28004513
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of novel 1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a]indole-3-carboxamide analogs in MCF-7 and MDA-MB-468 breast cancer cell lines.
Kim YJ; Pyo JS; Jung YS; Kwak JH
Bioorg Med Chem Lett; 2017 Feb; 27(3):607-611. PubMed ID: 27993518
[TBL] [Abstract][Full Text] [Related]
9. The effects of benzylsulfonyl-D-Ser-homoPhe-(4-amidino-benzylamide), a dual plasmin and urokinase inhibitor, on facial skin barrier function in subjects with sensitive skin.
Voegeli R; Wikstroem P; Campiche R; Steinmetzer T; Jackson E; Gempeler M; Imfeld D; Rawlings AV
Int J Cosmet Sci; 2017 Apr; 39(2):109-120. PubMed ID: 27434836
[TBL] [Abstract][Full Text] [Related]
10. [Synthesis and antithrombin activity of phosphoalanine-containing peptides].
Poiarkova SA; Fedoriak OD; Kibirev VK; Kukhar' VP
Bioorg Khim; 2003; 29(3):247-53. PubMed ID: 12845799
[TBL] [Abstract][Full Text] [Related]
11. Specificity of substrate analogue inhibitors of human urinary kallikrein.
Okunishi H; Burton J; Spragg J
Hypertension; 1985; 7(3 Pt 2):I72-5. PubMed ID: 3846567
[TBL] [Abstract][Full Text] [Related]
12. New fluorogenic substrates for alpha-thrombin, factor Xa, kallikreins, and urokinase.
Morita T; Kato H; Iwanaga S; Takada K; Kimura T
J Biochem; 1977 Nov; 82(5):1495-8. PubMed ID: 591514
[TBL] [Abstract][Full Text] [Related]
13. Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin.
Callas D; Bacher P; Iqbal O; Hoppensteadt D; Fareed J
Thromb Res; 1994 May; 74(3):193-205. PubMed ID: 8042188
[TBL] [Abstract][Full Text] [Related]
14. Low molecular peptides as potential inhibitors of plasmin.
Markowska A; Midura-Nowaczek K; Bruzgo I
Acta Pol Pharm; 2007; 64(4):355-8. PubMed ID: 18536161
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, molecular docking and anticancer studies of peptides and iso-peptides.
Jabeen F; Panda SS; Kondratyuk TP; Park EJ; Pezzuto JM; Ihsan-ul-Haq ; Hall CD; Katritzky AR
Bioorg Med Chem Lett; 2015 Aug; 25(15):2980-4. PubMed ID: 26048799
[TBL] [Abstract][Full Text] [Related]
16. Effects of peptidic antagonists of Grb2-SH2 on human breast cancer cells.
Chen CH; Chen MK; Jeng KC; Lung FD
Protein Pept Lett; 2010 Jan; 17(1):44-53. PubMed ID: 19508206
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological activity of ketomethylene pseudopeptide analogues as thrombin inhibitors.
Cheng L; Goodwin CA; Schully MF; Kakkar VV; Claeson G
J Med Chem; 1992 Sep; 35(18):3364-9. PubMed ID: 1527787
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activators in human breast cancer cell lines: hormonal regulation and properties.
Mangel WF; Toledo DL; Nardulli AM; Reiner GC; Norman MJ; Katzenellenbogen BS
J Steroid Biochem; 1988; 30(1-6):79-88. PubMed ID: 3386280
[TBL] [Abstract][Full Text] [Related]
19. Effects of epsilon-aminocaproiloaminoacids on the amidolytic activity of tissue plasminogen activator, urokinase and kallikrein.
Midura-Nowaczek K; Bruzgo I; Roszkowska-Jakimiec W; Markowska A
Acta Pol Pharm; 2004; 61(1):75-6. PubMed ID: 15259861
[TBL] [Abstract][Full Text] [Related]
20. Urokinase is a negative modulator of Egf-dependent proliferation and motility in the two breast cancer cell lines MCF-7 and MDA-MB-231.
Kozlova N; Samoylenko A; Drobot L; Kietzmann T
Mol Carcinog; 2016 Feb; 55(2):170-81. PubMed ID: 25641046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
